sur ABIVAX (EPA:ABVX)
Abivax submits its financial reports to French and American regulators
The biotechnology company Abivax announced the filing of its 2025 Universal Registration Document with the French Financial Markets Authority (AMF) and its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC). This filing, completed on March 23, 2026, includes detailed financial information and corporate governance reports.
Abivax, which specializes in developing treatments for chronic inflammatory diseases, also provided its auditors' reports. These documents are available online on the websites of Abivax, the AMF (French Financial Markets Authority), and the SEC (Security and Investment Company), making them easily accessible to investors and stakeholders.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX